VBI Vaccines rises on 'orphan drug' tag for vaccine candidate

VBI Vaccines

22/06/2022 15:57

** VBI Vaccines Inc's shares  VBIV.O  rise 8% to $0.83 in
early trade
    ** Receives U.S. FDA "orphan drug" designation for vaccine
candidate VBI-1901 for treatment of glioblastoma, a cancer of
nerve cells linked to cytomegalovirus  urn:newsml:reuters.com:*:nBw1HqysXa
    ** All 3 brokerages covering the stock rate it "buy" or
higher; their median PT is $6 - Refinitiv data
    ** Despite session's gain, stock down 64.5% YTD

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))